These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 17333566)

  • 1. Strengthening the regulation of clinical trials and bioresearch monitoring.
    FDA Consum; 2006; 40(6):35. PubMed ID: 17333566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of escalating regulatory requirements on the conduct of clinical research.
    Gordon BG; Kessinger A; Mann SL; Prentice ED
    Cytotherapy; 2003; 5(4):309-13. PubMed ID: 12944237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of clinical investigations; availability of guideline--FDA. Notice.
    Fed Regist; 1988 Feb; 53(31):4723-4. PubMed ID: 10285639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health research oversight in Africa.
    Noor RA
    Acta Trop; 2009 Nov; 112 Suppl 1():S63-70. PubMed ID: 19698692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New clinical trials policy at FDA.
    Vastag B
    Nat Biotechnol; 2006 Sep; 24(9):1043. PubMed ID: 16964196
    [No Abstract]   [Full Text] [Related]  

  • 6. Investigator financial disclosures and its effect on research subjects.
    Gibbs JN; Guagnano GA
    Food Drug Law J; 2007; 62(4):727-37. PubMed ID: 18557228
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA oversight of cell therapy clinical trials.
    Au P; Hursh DA; Lim A; Moos MC; Oh SS; Schneider BS; Witten CM
    Sci Transl Med; 2012 Aug; 4(149):149fs31. PubMed ID: 22932219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innovative strategies for early clinical R&D.
    Butz RF; Morelli G
    IDrugs; 2008 Jan; 11(1):36-41. PubMed ID: 18175261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Making clinical data widely available.
    Kaiser J
    Science; 2008 Oct; 322(5899):217-8. PubMed ID: 18845745
    [No Abstract]   [Full Text] [Related]  

  • 10. Collecting race and ethnicity data in clinical human research projects.
    Maloney DM
    Hum Res Rep; 2003 Mar; 18(3):1-2. PubMed ID: 14603942
    [No Abstract]   [Full Text] [Related]  

  • 11. They are from the government and they really are here to help you.
    Woosley RL
    J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889
    [No Abstract]   [Full Text] [Related]  

  • 12. Perspectives on the U.S. FDA Bioresearch Monitoring Program.
    Gamet JE
    Qual Assur; 1995 Mar; 4(1):12-9. PubMed ID: 8520859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA's Bioresearch Monitoring Program.
    Kelsey FO
    Methods Find Exp Clin Pharmacol; 1982; 4(7):503-8. PubMed ID: 7169836
    [No Abstract]   [Full Text] [Related]  

  • 14. Confidentiality laws and secrecy in medical research: improving public access to data on drug safety.
    Kesselheim AS; Mello MM
    Health Aff (Millwood); 2007; 26(2):483-91. PubMed ID: 17339677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The disfranchisement of fertile women in clinical trials: the legal ramifications of and solutions for rectifying the knowledge gap.
    Bowles LE
    Vanderbilt Law Rev; 1992 May; 45(4):877-920. PubMed ID: 16047448
    [No Abstract]   [Full Text] [Related]  

  • 16. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of the current regulatory environment on clinical research: An overview.
    Finlayson SR
    Surgery; 2009 Jun; 145(6):626-30. PubMed ID: 19486763
    [No Abstract]   [Full Text] [Related]  

  • 18. Charging for investigational drugs under an investigational new drug application. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trials bureaucracy: unintended consequences of well-intentioned policy.
    Califf RM
    Clin Trials; 2006; 3(6):496-502. PubMed ID: 17170032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Food and Drug Administration public hearing on the draft guidance for exception from informed consent requirements for emergency research: testimony of Novo Nordisk.
    Weiskopf RB;
    Acad Emerg Med; 2007 Apr; 14(4):e71-3. PubMed ID: 17322571
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.